

REMARKS

The specification has been amended to have a title reflective of the claimed subject matter and to recite the current history of this divisional application. Additionally, the updated Sequence Listing comprising 35 sequences on 64 pages is requested to be entered into the Specification, replacing the previous Sequence Listing in Patent-In Version 2. A paper copy of the updated Sequence Listing, as well as a computer diskette, and statements as required under 37 C.F.R. §§1.821(f) and (g) are provided herewith.

Please cancel claims 1-24, 26, and 28-41 without prejudice to filing one or more divisional applications. With this amendment, there are now three claims pending, namely claims 25, 27 and 42. These claims are drawn to antibodies and were deemed Group II as part of a two-way restriction requirement in the related U.S. Application Serial No. 09/873,873. Applicants are presently pursuing the antibody claims drawn to SEQ ID NO:34. Claim 25 has been amended to read on SEQ ID NO:34. New dependent claim 42 finds support in at least section 2.2 of the specification. Pursuant to 37 C.F.R. § 1.118(a), Applicants respectfully submit that the foregoing amendments do not introduce any new material into the application.

The Commissioner is authorized to charge the filing fee and claims fee to Deposit Account No. 01-2508/11792.0210.DVUS03.

Should any additional fees be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Deposit Account No. 01-2508/11792. 0210.DVUS03.

Respectfully submitted,



Amy G. Klann
Reg. No. 48,155
Agent for Assignee
MONSANTO TECHNOLOGY LLC

HOWREY SIMON ARNOLD & WHITE, LLP
750 Bering Drive
Houston, Texas 77057-2198
(713) 787-1400

Date: April 2, 2004